Immunotherapy benefit assessment is a comprehensive laboratory and clinical evaluation designed to predict, measure, and monitor a patient's likelihood of responding to immune checkpoint inhibitors and other cancer immunotherapies. By integrating biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and circulating tumor DNA (ctDNA) dynamics with imaging-based response criteria, this assessment helps oncologists select optimal candidates, detect early response or resistance, and manage phenomena such as pseudoprogression. This article details the sample requirements, testing items, analytical methods, clinical applications, and frequently asked questions related to professional immunotherapy benefit evaluation.
Technical Overview
Immunotherapy benefit assessment refers to the systematic evaluation of biomarkers and clinical indicators that predict or reflect a patient's therapeutic benefit from cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 pathways. Unlike conventional chemotherapy, immunotherapy reactivates the patient's own antitumor immune response, which means that responders may experience durable disease control lasting years, while non-responders may derive little benefit or even experience hyperprogression. Accurate benefit assessment therefore serves two complementary purposes: pre-treatment prediction of response probability and on-treatment monitoring of actual therapeutic effect.
Pre-treatment predictive evaluation centers on well-validated biomarkers, including PD-L1 expression measured as the Tumor Proportion Score (TPS) or Combined Positive Score (CPS), tumor mutational burden (TMB), microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) status, tumor-infiltrating lymphocyte (TIL) density, and T-cell-inflamed gene expression profiles. Concurrently, resistance-associated alterations such as STK11, KEAP1, JAK1/2, and B2M mutations, as well as EGFR or ALK driver mutations in certain tumor types, may inform the likelihood of primary non-response.
On-treatment monitoring relies on non-invasive dynamic biomarkers such as circulating tumor DNA (ctDNA) clearance, peripheral blood lymphocyte subset profiling, and cytokine levels, together with imaging assessment performed according to immune-related response criteria (iRECIST), which account for atypical response patterns such as pseudoprogression. All testing described in this article is performed using validated assays under quality management frameworks consistent with ISO 15189 (medical laboratory requirements) and ISO/IEC 17025 (testing and calibration laboratory competence), in accredited third-party laboratories or qualified clinical laboratory settings.
Testing Samples
Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue
FFPE tissue blocks or sections obtained from surgical resection or core needle biopsy are the primary sample type for tissue-based biomarker analysis. Samples should be fixed in 10% neutral buffered formalin for 6 to 48 hours and should contain a viable tumor cellularity of at least 20% for reliable PD-L1 scoring and TMB calculation. A minimum of 5 to 10 unstained sections (4 to 5 micrometers thick) mounted on positively charged slides, or one representative tissue block, is typically requested. Pathologist-verified tumor content is documented before analysis, and macrodissection is performed when necessary to enrich tumor regions.
Fresh or Frozen Tumor Tissue
Fresh tissue collected in sterile, nucleic acid-preserving transport media or snap-frozen tissue stored at -80°C may be submitted for whole-exome sequencing, RNA sequencing, and immune cell profiling studies that require high-quality nucleic acids. Fresh samples should be delivered within 24 to 48 hours of collection under validated cold-chain conditions to preserve RNA integrity and lymphocyte viability.
Whole Blood and Plasma
Peripheral whole blood collected in EDTA tubes is used for germline control DNA, lymphocyte subset analysis by flow cytometry, and genomic analysis. Plasma separated from 10 to 20 mL of blood collected in cell-stabilizing tubes is used for cell-free DNA (cfDNA) extraction and ctDNA-based dynamic monitoring. Blood samples for ctDNA analysis should be processed within the stabilization window specified by the validated workflow to minimize leukocyte DNA contamination.
Serum and Other Body Fluids
Serum samples are accepted for cytokine and soluble immune checkpoint quantification, while malignant ascites, pleural effusion, or cerebrospinal fluid may be submitted for tumor cell enrichment and biomarker testing in patients without accessible tissue lesions. These alternative specimens expand testing accessibility for advanced-stage patients.
Testing Items
Immunotherapy benefit assessment encompasses the following core testing categories, which may be ordered individually or as an integrated panel:
- PD-L1 expression scoring: Tumor Proportion Score (TPS), Combined Positive Score (CPS), and immune cell (IC) scoring to determine eligibility for anti-PD-1 and anti-PD-L1 monotherapy or combination regimens.
- Tumor mutational burden (TMB): Tissue TMB (tTMB) and blood TMB (bTMB), reported as mutations per megabase (mut/Mb), with commonly applied clinical interpretive thresholds at approximately 10 mut/Mb.
- Microsatellite instability and mismatch repair status: MSI detection across standard mononucleotide and dinucleotide markers plus immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 proteins to identify MSI-H or dMMR tumors with high probability of durable immunotherapy benefit.
- Tumor-infiltrating lymphocyte profiling: Quantification of CD3-positive, CD4-positive, and CD8-positive T cells, FOXP3-positive regulatory T cells, and calculated CD8-to-FOXP3 ratios as indicators of the pre-existing antitumor immune microenvironment.
- Predictive and resistance genomic alterations: Detection of driver mutations (EGFR, ALK, MET exon 14), resistance-associated alterations (STK11, KEAP1, JAK1, JAK2, B2M), HLA locus heterozygosity loss, MDM2 or MDM4 amplification associated with hyperprogression risk, and copy-number burden.
- Gene expression profiles (GEP): Interferon-gamma signaling signatures, T-cell-inflamed gene expression scores, and immune cytolytic activity markers such as GZMB and PRF1 transcripts.
- ctDNA dynamic monitoring: Baseline ctDNA quantification, serial variant allele frequency tracking, molecular residual disease (MRD) assessment after curative-intent therapy, and early ctDNA clearance kinetics as a predictor of clinical benefit.
- Peripheral immune monitoring: Lymphocyte subset enumeration (T cells, B cells, NK cells, Tregs), cytokine panels (IFN-gamma, IL-2, IL-6, IL-8, TNF-alpha), and soluble PD-1 and PD-L1 measurement.
Testing Methods
Each testing item is performed using analytically validated methods with defined performance characteristics for sensitivity, specificity, precision, limit of detection, and reportable range:
- Immunohistochemistry (IHC): PD-L1 staining is performed on validated automated platforms using clinically validated antibody clones, with scoring conducted by qualified pathologists according to established interpretive algorithms. Mismatch repair protein IHC and multiplex TIL staining follow standardized laboratory-developed procedures with appropriate positive and negative controls.
- Next-generation sequencing (NGS): TMB and comprehensive genomic profiling are performed using targeted hybrid-capture panels covering at least 1 megabase of coding sequence or whole-exome sequencing, with matched germline or normal tissue subtraction when applicable. Bioinformatic pipelines filter germline variants and artifacts, and TMB values are calibrated against reference standards.
- Polymerase chain reaction (PCR) methods: MSI status is determined by multiplex fluorescent PCR with capillary electrophoresis across validated microsatellite loci, with results categorized as microsatellite stable (MSS), MSI-low, or MSI-high. Real-time quantitative PCR supports targeted resistance mutation detection.
- Droplet digital PCR and cfDNA sequencing: ctDNA monitoring employs ultra-deep sequencing of patient-specific variant panels or digital PCR assays, achieving allele fractions below 0.1% for MRD-level sensitivity, with error-suppression strategies such as molecular barcoding.
- Flow cytometry: Multiparameter flow cytometry quantifies peripheral lymphocyte subsets and activation markers using standardized gating strategies and instrument daily quality control with reference beads.
- Immunoassays: Cytokines and soluble checkpoints are quantified by ELISA or multiplex bead-based immunoassays with calibration curves and inter-assay coefficient of variation within validated acceptance limits.
- Radiological response assessment: Tumor measurements from contrast-enhanced CT or MRI are evaluated according to iRECIST, distinguishing unconfirmed progressive disease from confirmed progression and permitting continued treatment through initial apparent progression when clinically appropriate.
All methods undergo validation in accordance with ISO 15189 and ISO/IEC 17025 quality principles, with participation in external proficiency testing programs, documented chain of custody for every specimen, and comprehensive quality control review prior to result release.
Applications
Immunotherapy benefit assessment supports clinical decision-making across a broad range of solid tumors and treatment settings:
- Non-small cell lung cancer (NSCLC): PD-L1 TPS of 50% or greater supports first-line immune checkpoint monotherapy, while combined PD-L1, TMB, and driver mutation testing guides selection among monotherapy, chemoimmunotherapy, and targeted therapy approaches.
- Melanoma: Baseline TMB, TIL density, and ctDNA kinetics inform the choice of combination checkpoint blockade versus sequential therapy and enable early identification of response within weeks of treatment initiation.
- Gastrointestinal cancers: MSI-H and dMMR screening is recommended for all colorectal cancers and increasingly for gastric, esophageal, and pancreatic cancers; PD-L1 CPS scoring guides treatment selection in gastroesophageal and esophageal malignancies.
- Pan-cancer tissue-agnostic indications: MSI-H and dMMR status, together with high TMB, may qualify patients for checkpoint inhibitor therapy regardless of primary tumor site.
- Genitourinary, head and neck, and gynecologic malignancies: PD-L1 expression and ctDNA monitoring support therapeutic selection and early response assessment in urothelial carcinoma, head and neck squamous cell carcinoma, cervical cancer, and triple-negative breast cancer.
- On-treatment management: Serial ctDNA and imaging evaluation differentiate pseudoprogression from true progression, identify hyperprogression requiring prompt treatment discontinuation, and support decisions on treatment extension beyond two years in deep responders.
- Post-operative surveillance: Molecular residual disease detection using ctDNA identifies patients at high risk of relapse who may benefit from adjuvant immunotherapy clinical trials.
- Clinical research support: Validated biomarker data serve as stratification factors and pharmacodynamic endpoints in immunotherapy clinical trials and real-world evidence studies.
FAQ
Q: What is immunotherapy benefit assessment and who should undergo it?
A: It is a structured laboratory and clinical evaluation that estimates the probability and extent of benefit from immunotherapy. It is recommended for patients with advanced or metastatic solid tumors being considered for immune checkpoint inhibitors, patients experiencing atypical treatment courses, and patients undergoing surveillance after curative-intent therapy.
Q: What is the difference between PD-L1 TPS and CPS?
A: TPS counts only viable tumor cells with membranous PD-L1 staining, whereas CPS counts PD-L1-positive tumor cells plus lymphocytes and macrophages, divided by total viable tumor cells. CPS is applied mainly in gastroesophageal, cervical, urothelial, and head and neck cancers, while TPS is standard in NSCLC.
Q: What TMB level is considered high?
A: Although cutoffs vary by tumor type and assay, approximately 10 mutations per megabase is a widely used interpretive threshold associated with increased likelihood of immunotherapy benefit. Results must always be interpreted alongside PD-L1, MSI status, and clinical context.
Q: Can testing be performed if no tumor tissue is available?
A: Yes. Blood-based assays, including bTMB, cfDNA mutation profiling, and MSI detection from plasma, provide a validated alternative, although tissue testing remains the reference approach whenever a specimen can be obtained.
Q: How is pseudoprogression distinguished from true progression?
A: iRECIST criteria require radiological confirmation of progression at a follow-up scan, typically 4 to 8 weeks later. A rapid decline in ctDNA levels despite radiographic growth strongly supports pseudoprogression, whereas rising ctDNA with clinical deterioration indicates true progression.
Q: How often should on-treatment monitoring be performed?
A: ctDNA monitoring is commonly performed at baseline, then every 4 to 12 weeks aligned with imaging cycles. Lymphocyte and cytokine monitoring may be performed more frequently when immune-related adverse events are suspected.
Q: Do favorable biomarkers guarantee a response?
A: No. Even PD-L1-high, MSI-H, or TMB-high tumors may not respond, and occasional responders have none of these markers. Biomarker results are probabilistic tools that must be integrated with clinical judgment, performance status, comorbidities, and patient preference.
Q: What is the typical turnaround time?
A: PD-L1 IHC and MMR testing generally require 3 to 5 business days, MSI PCR 5 to 7 business days, and comprehensive NGS profiling 10 to 14 business days, depending on sample quality and panel complexity. Urgent clinical situations can be communicated to the laboratory for expedited handling.
